Compare EXPO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | ABCL |
|---|---|---|
| Founded | 1967 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 1996 | 2020 |
| Metric | EXPO | ABCL |
|---|---|---|
| Price | $66.53 | $12.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $88.00 | $8.40 |
| AVG Volume (30 Days) | 346.8K | ★ 4.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $582,014,000.00 | $75,128,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $8.50 | $21.85 |
| P/E Ratio | $56.40 | ★ N/A |
| Revenue Growth | 4.21 | ★ 160.56 |
| 52 Week Low | $51.91 | $2.75 |
| 52 Week High | $81.95 | $13.18 |
| Indicator | EXPO | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 65.43 |
| Support Level | $64.38 | $10.38 |
| Resistance Level | $69.46 | N/A |
| Average True Range (ATR) | 1.52 | 0.59 |
| MACD | -0.30 | -0.00 |
| Stochastic Oscillator | 35.81 | 79.02 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.